Literature DB >> 2969764

Quinolinic acid lesions of rat striatum abolish D1- and D2-dopamine receptor-mediated catalepsy.

S F Calderon1, P R Sanberg, A B Norman.   

Abstract

The selective D1-dopamine receptor antagonist SCH23390 and the more D2-selective antagonist haloperidol produced marked catalepsy in rats. The novel excitotoxin quinolinic acid (QA) selectively destroys striatal neurons when injected directly into the striatum. Bilateral QA lesions of the rat striatum (150 nmol and 225 nmol per side) abolished the cataleptic response to both SCH23390 and haloperidol. These data indicate that the D1- and/or D2-dopamine receptors which mediate the cataleptic response are restricted to QA-sensitive neurons in the rat striatum.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2969764     DOI： 10.1016/0006-8993(88)91584-3

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


  9 in total

Review 1.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  The striatal dopaminergic catalepsy mechanism is not necessary for the expression of pontine catalepsy produced by carbachol injections into the pontine reticular formation.

Authors:  Z Elazar; N Peleg; M Paz; G Ring
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

3.  The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?

Authors:  J Srinivasan; Werner J Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-29       Impact factor: 3.000

4.  The adenosine receptor antagonist theophylline induces a monoamine-dependent increase of the anticataleptic effects of NMDA receptor antagonists.

Authors:  W Hauber; M Münkle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

5.  The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.

Authors:  Kurt Rasmussen; Mei-Ann Hsu; Stephen Noone; Bryan G Johnson; Linda K Thompson; Susan K Hemrick-Luecke
Journal:  Schizophr Bull       Date:  2007-07-28       Impact factor: 9.306

6.  MK-801-induced stereotypy and its antagonism by neuroleptic drugs.

Authors:  P I Tiedtke; C Bischoff; W J Schmidt
Journal:  J Neural Transm Gen Sect       Date:  1990

7.  Discrete quinolinic acid lesions of the lateral but not of the medial caudate-putamen reversed haloperidol-induced catalepsy in rats.

Authors:  W Hauber; W J Schmidt
Journal:  J Neural Transm Gen Sect       Date:  1993

8.  Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol.

Authors:  H L Andersen; I C Kilpatrick
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

9.  Glycine site antagonists abolish dopamine D2 but not D1 receptor mediated catalepsy in rats.

Authors:  B D Kretschmer; B Winterscheid; W Danysz; W J Schmidt
Journal:  J Neural Transm Gen Sect       Date:  1994
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.